跳至主要内容
临床试验/EUCTR2017-003104-42-DK
EUCTR2017-003104-42-DK进行中(未招募)1 期

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects with X-Linked Retinitis Pigmentosa Previously Treated with Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study

ightstaRx Ltd (A Biogen Company)0 个研究点目标入组 330 人开始时间: 2020年7月1日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • CHM Participants:
  • a. Are willing and able to give informed consent for participation in the study, and
  • b. Have participated in and exited from an interventional study that investigated the safety and efficacy of a sub-retinal injection of AAV2-REP1 for CHM
  • XLRP Participants:
  • a. Are willing and able to give informed consent for participation in the study
  • b. Have received a sub-retinal injection of AAV8-RPGR for XLRP and have exited an antecedent study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 330
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • In the opinion of the investigator and/or the Sponsor, it is not in the participant's best interest to participate in the study.

研究者

发起方
ightstaRx Ltd (A Biogen Company)

相似试验